TABLE 4.
Phase 2 demographics
| Group | n | Age (mean [SD]) (yr) | Wt (mean [SD]) (kg)a | Geometric mean anti-PA IgG (ng/ml [%CV])b | Geometric mean TNA ED50/NF50b | Spore challenge LD50 (mean [SD]) |
|---|---|---|---|---|---|---|
| 1 (survivor group 1, phase 1) | 13 | 17.0 (0.00) | 3.8 (0.43) | 2,700 (77) | 256/0.321 | 238.1 (58.6) |
| 2 (survivor group 2, phase 1) | 20 | 17.0 (0.00) | 3.9 (0.41) | 3,140 (212) | 383/0.558 | 209.2 (41.0) |
| 3 (survivor group 3, phase 1) | 19 | 17.0 (0.00) | 3.9 (0.39) | 1,520 (343) | 163/0.287 | 207.1 (37.4) |
| 5 (naive controls) | 12 | 11.3 (0.98) | 3.9 (0.12) | <LOQ (0) | NA | 221.9 (47.0) |
a
Measured on day of challenge.
b
Measured only in phase 1 survivors. LOQ, limit of quantitation = 50.0 ng/ml for anti-PA IgG ELISA; NA, not applicable.